<li>albiglutide<p>albiglutide, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>alogliptin<p>alogliptin, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .</p></li><li>amiodarone<p>amiodarone will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>aripiprazole<p>aripiprazole, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>atazanavir<p>atazanavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>bexarotene<p>bexarotene increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.</p></li><li>bitter melon<p>bitter melon increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>bosentan<p>bosentan will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>canagliflozin<p>nateglinide, canagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>carvedilol<p>nateglinide will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>cinnamon<p>cinnamon increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofloxacin<p>ciprofloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.</p></li><li>clarithromycin<p>clarithromycin decreases levels of nateglinide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. May result in hypoglycemia; monitor glucose levels closely.</p></li><li>clozapine<p>clozapine, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>dapagliflozin<p>nateglinide, dapagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.</p></li><li>darunavir<p>darunavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>divalproex sodium<p>divalproex sodium will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>dobutamine<p>dobutamine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>dopamine<p>dopamine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>dulaglutide<p>dulaglutide, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>eltrombopag<p>nateglinide will increase the level or effect of eltrombopag by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>eltrombopag increases levels of nateglinide by decreasing metabolism. Use Caution/Monitor. OATP transporter protein inhibition.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>empagliflozin<p>empagliflozin, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.</p></li><li>ephedrine<p>ephedrine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>epinephrine<p>epinephrine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>ethotoin<p>nateglinide will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>etravirine<p>etravirine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>nateglinide will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>felbamate<p>felbamate will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fleroxacin<p>fleroxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>fosamprenavir<p>fosamprenavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>fosphenytoin<p>nateglinide will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fosphenytoin will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Inducers of CYP2C9 decrease levels of  nateglinide by increasing its metabolism.   Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>gemifloxacin<p>gemifloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>iloperidone<p>iloperidone, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>imatinib<p>imatinib will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>insulin aspart<p>nateglinide, insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin aspart protamine/insulin aspart<p>nateglinide, insulin aspart protamine/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec<p>nateglinide, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec/insulin aspart<p>nateglinide, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin detemir<p>nateglinide, insulin detemir.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glargine<p>nateglinide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glulisine<p>nateglinide, insulin glulisine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin inhaled<p>nateglinide, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin isophane human/insulin regular human<p>nateglinide, insulin isophane human/insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro<p>nateglinide, insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro protamine/insulin lispro<p>nateglinide, insulin lispro protamine/insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin nph<p>nateglinide, insulin nph.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin regular human<p>nateglinide, insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>isoproterenol<p>isoproterenol decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>lanreotide<p>nateglinide, lanreotide. Other (see comment). Use Caution/Monitor. 
Comment: Somatostatin analogues may potentiate or attenuate nateglinide's hypoglycemic action.</p></li><li>leflunomide<p>leflunomide will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>levothyroxine<p>levothyroxine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>liotrix<p>liotrix decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>liraglutide<p>liraglutide, nateglinide.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Concurrent use may increase risk of hypoglycemia; monitor glucose levels.</p></li><li>lisdexamfetamine<p>lisdexamfetamine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>lopinavir<p>lopinavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>losartan<p>nateglinide will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, nateglinide. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>lurasidone<p>lurasidone, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>marijuana<p>marijuana decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>methylphenidate<p>methylphenidate decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>metreleptin<p>nateglinide, metreleptin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nelfinavir<p>nelfinavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of nateglinide by  Other (see comment). Use Caution/Monitor. Reports of hyperglycemia due to insulin resistance with protease inhibitors. </p></li><li>nilotinib<p>nilotinib will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>nitisinone<p>nitisinone will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>norepinephrine<p>norepinephrine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>norfloxacin<p>norfloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>omeprazole<p>omeprazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>paliperidone<p>paliperidone, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>parecoxib<p>nateglinide will increase the level or effect of parecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>phenytoin<p>nateglinide will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>phenytoin will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Inducers of CYP2C9 decrease levels of  nateglinide by increasing its metabolism.   Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>primidone<p>primidone will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>pseudoephedrine<p>pseudoephedrine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>quetiapine<p>quetiapine, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>saquinavir<p>saquinavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>shark cartilage<p>shark cartilage increases effects of nateglinide by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>somatropin<p>somatropin decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Inducers of CYP2C9 decrease levels of  nateglinide by increasing its metabolism.   Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>sulfadiazine<p>sulfadiazine increases levels of nateglinide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole increases levels of nateglinide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of nateglinide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfisoxazole<p>sulfisoxazole increases levels of nateglinide by plasma protein binding competition. Use Caution/Monitor.</p></li><li>thyroid desiccated<p>thyroid desiccated decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>ticlopidine<p>ticlopidine will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>tipranavir<p>tipranavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>valproic acid<p>valproic acid will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>warfarin<p>nateglinide will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide decreases levels of nateglinide by increasing renal clearance. Use Caution/Monitor.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li>